Matches in Wikidata for { <http://www.wikidata.org/entity/Q91160296> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- Q91160296 description "artículu científicu espublizáu n'agostu de 2018" @default.
- Q91160296 description "scientific article published on 24 August 2018" @default.
- Q91160296 description "wetenschappelijk artikel" @default.
- Q91160296 description "наукова стаття, опублікована в серпні 2018" @default.
- Q91160296 name "A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma" @default.
- Q91160296 name "A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma" @default.
- Q91160296 type Item @default.
- Q91160296 label "A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma" @default.
- Q91160296 label "A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma" @default.
- Q91160296 prefLabel "A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma" @default.
- Q91160296 prefLabel "A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma" @default.
- Q91160296 P1433 Q91160296-1A549AA6-D686-40F8-B949-7F135A1A6741 @default.
- Q91160296 P1476 Q91160296-1818EC5D-9649-448A-B9E3-D57A2C061C6C @default.
- Q91160296 P2093 Q91160296-024FADEA-C49D-422A-9C96-1A18F7E217CC @default.
- Q91160296 P2093 Q91160296-07887443-1E53-424E-931B-68ACC0CA02D7 @default.
- Q91160296 P2093 Q91160296-090E782C-F2D4-48CB-B3DF-834588FE0899 @default.
- Q91160296 P2093 Q91160296-1379C2C7-3A2B-44B0-BC77-DA6979C87CC9 @default.
- Q91160296 P2093 Q91160296-146DA43E-D0B3-4B49-8751-8C2B911A0C03 @default.
- Q91160296 P2093 Q91160296-2C22C464-7F1B-4569-963E-2054B887B6F6 @default.
- Q91160296 P2093 Q91160296-494A1CA9-56B6-48BC-8CEF-97B892800ED5 @default.
- Q91160296 P2093 Q91160296-548618B6-F789-4FF2-8C99-9ABFE05B53E4 @default.
- Q91160296 P2093 Q91160296-71DD2155-4A8F-4603-AC3B-5C26BAB79B38 @default.
- Q91160296 P2093 Q91160296-88B08AF5-86DE-4FCA-BEF4-9EDC4CCAD045 @default.
- Q91160296 P2093 Q91160296-9A61442D-DD4C-4E24-871A-5398447BFF28 @default.
- Q91160296 P2093 Q91160296-9FF76470-60CD-4291-9A8E-73BE9FD309B9 @default.
- Q91160296 P2093 Q91160296-A658AA90-6704-4F77-887E-6146999FF524 @default.
- Q91160296 P2093 Q91160296-F12D70E4-6013-4E19-9218-F85728269AB8 @default.
- Q91160296 P2093 Q91160296-FC051CD0-8916-4AC6-ABE8-C7E673E2C694 @default.
- Q91160296 P304 Q91160296-E9CC3593-0470-49EE-A44E-39A371E0E862 @default.
- Q91160296 P31 Q91160296-5887DEF2-62B7-45F2-AD68-B47095209887 @default.
- Q91160296 P356 Q91160296-D46B33D4-8D64-4767-A532-ACF04170618B @default.
- Q91160296 P478 Q91160296-9C39D3BB-9075-44B2-84B7-8ABE92462928 @default.
- Q91160296 P50 Q91160296-250C7999-C55E-433B-919C-48EF1564DF59 @default.
- Q91160296 P50 Q91160296-6A0719BF-9144-4C6D-AD68-6AD0B8CB4005 @default.
- Q91160296 P577 Q91160296-DF568F5E-198E-48B9-971F-C58D3A351DC3 @default.
- Q91160296 P698 Q91160296-F9C0F8D9-3B86-4B1D-9600-D32F1A0BF722 @default.
- Q91160296 P921 Q91160296-2369E05E-D85C-4B37-96E1-957050FEF52C @default.
- Q91160296 P921 Q91160296-AD9ADBAA-EAFC-4960-878D-C3BB7382E8AD @default.
- Q91160296 P921 Q91160296-B62982E4-1959-4091-8DFC-2FD4C029F139 @default.
- Q91160296 P921 Q91160296-D0D0D994-8D89-4B5C-8258-F278CAA8570F @default.
- Q91160296 P356 J.EJCA.2018.07.007 @default.
- Q91160296 P698 30149366 @default.
- Q91160296 P1433 Q332260 @default.
- Q91160296 P1476 "A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma" @default.
- Q91160296 P2093 "Chiara Pircher" @default.
- Q91160296 P2093 "Clara Fugazza" @default.
- Q91160296 P2093 "Claudio Doglioni" @default.
- Q91160296 P2093 "Domenica Ceraulo" @default.
- Q91160296 P2093 "Gianpaolo Balzano" @default.
- Q91160296 P2093 "Marta Chiaravalli" @default.
- Q91160296 P2093 "Massimo Falconi" @default.
- Q91160296 P2093 "Michele Reni" @default.
- Q91160296 P2093 "Paolo Giorgio Arcidiacono" @default.
- Q91160296 P2093 "Paolo Passoni" @default.
- Q91160296 P2093 "Renato Castoldi" @default.
- Q91160296 P2093 "Roberto Nicoletti" @default.
- Q91160296 P2093 "Silvia Zanon" @default.
- Q91160296 P2093 "Stefano Partelli" @default.
- Q91160296 P2093 "Umberto Peretti" @default.
- Q91160296 P304 "95-102" @default.
- Q91160296 P31 Q13442814 @default.
- Q91160296 P356 "10.1016/J.EJCA.2018.07.007" @default.
- Q91160296 P478 "102" @default.
- Q91160296 P50 Q56629673 @default.
- Q91160296 P50 Q84736390 @default.
- Q91160296 P577 "2018-08-24T00:00:00Z" @default.
- Q91160296 P698 "30149366" @default.
- Q91160296 P921 Q18556189 @default.
- Q91160296 P921 Q412415 @default.
- Q91160296 P921 Q420207 @default.
- Q91160296 P921 Q42824440 @default.